Sorafenib worsens GVHD and shortens survival when given after a T cell–replete allogeneic SCT in mice with RENCA tumors. GVHD score and survival in tumor bearing mice undergoing allogeneic SCT using BM + splenocytes with or with sorafenib given by oral gavage after transplantation. GVHD score was assessed by the following symptoms: alopecia (0-4 points), hunched posture (0-2 points), ear or eye irritation (0-1 points). Error bars (left panel) show standard error of the mean.